Lv2
140 积分 2023-02-07 加入
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
1个月前
已完结
Ifupinostat: First Approval
1个月前
已完结
Mirikizumab: First Approval
1个月前
已完结
Fosrolapitant/Palonosetron: First Approval
1个月前
已完结
[A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C]
2个月前
已完结
Clinical Effects of Recently Developed Antipsychotic Drugs in Schizophrenia
2个月前
已完结
Ivarmacitinib Sulfate: First Approval
2个月前
已完结
TKIs in combination with immunotherapy for hepatocellular carcinoma
3个月前
已完结
Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019
5个月前
已完结
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe
8个月前
已完结
皖公网安备34019202002308